Cencora
Cencora, formerly known as the Clinical Research Division of AmerisourceBergen, is a prominent player in the global pharmaceutical services industry. Headquartered in the United States, Cencora operates extensively across North America, Europe, and Asia, providing comprehensive solutions that span clinical trial management, supply chain logistics, and commercialisation services. Founded in 2022, the company has quickly established itself as a leader in the sector, leveraging its extensive expertise to support biopharmaceutical companies in bringing innovative therapies to market. Cencora's core offerings include tailored clinical trial services and advanced supply chain solutions, distinguished by their commitment to quality and efficiency. With a focus on enhancing patient access to critical medications, Cencora has achieved notable milestones, positioning itself as a trusted partner in the healthcare landscape. Its dedication to innovation and excellence continues to drive its success in an ever-evolving market.
DitchCarbon Score
How does Cencora's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cencora's score of 57 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cencora's reported carbon emissions
In 2024, Cencora reported total greenhouse gas emissions of approximately 135,087,000 kg CO2e for Scope 1, 79,063,000 kg CO2e for Scope 2, and a significant 40,504,084,000 kg CO2e for Scope 3 emissions. This reflects a comprehensive approach to emissions reporting, covering all relevant scopes. Cencora has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 54.6% by FY2032, using FY2019 as the baseline year. Additionally, the company has pledged that 82% of its suppliers, based on spend, will have science-based targets by FY2027. These targets align with the necessary reductions to limit global warming to 1.5°C, demonstrating Cencora's commitment to sustainability and responsible environmental stewardship. The company's emissions data and reduction targets highlight its proactive stance in addressing climate change and its impact within the healthcare sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 98,742,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 100,593,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 19,881,916,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cencora is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
